AbbVievsHaemonetics

ABBV and HAE stock compared: price, dividend, valuation and results, from SEC filings.

HAE

Haemonetics Corporation

$122.94

Value $5.6B

+0.19%
HAE's page

AbbVie (ABBV) has a market value of $522B and Haemonetics (HAE) $5.6B. Over the last year, with dividends, ABBV moved +30.3% and HAE +68.1%. The P/E is 50.7 for ABBV and 53.8 for HAE. Dividend yield: ABBV 2.35%, HAE none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    HAE$5.6B

    ABBV is 93 times HAE

  • Revenue, 12 months

    ABBV$66.0B

    HAE$1.4B

    ABBV is 48 times HAE

  • Net income, 12 months

    ABBV$10.3B

    HAE$104M

    ABBV is 100 times HAE

  • Operating margin

    ABBV32.2%

    HAE12.8%

    19.4 points apart

  • ROIC

    ABBV25.7%

    HAE6.3%

    19.4 points apart

  • P/E

    ABBV50.7

    HAE53.8

    HAE is 1.1 times ABBV

  • Dividend yield

    ABBV2.4%

    HAE0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.5%

    HAE+105.0%

    96.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.5%

HAE+105.0%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsHAEWith dividends
1 year since November 12, 2025+30.3%Price +26.5%+68.1%Price +68.1%
3 years since November 13, 2023+135.3%+33.0% a yearPrice +112.8%+41.8%+12.4% a yearPrice +41.8%
5 years since November 12, 2021+201.5%+24.7% a yearPrice +152.2%+105.0%+15.4% a yearPrice +105.0%
10 years since November 15, 2016+605.5%+21.6% a yearPrice +369.3%+216.3%+12.2% a yearPrice +216.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieHAEHaemonetics

Valuation

ABBVHAE
Valuation
Price$295.03$122.94
Market value$522B$5.6B
Enterprise value (EV)$592B$6.5B
P/E50.753.8
P/E, 5-year median57.036.9
P/B–6.2
EV/EBIT27.936.5
Free cash flow yield3.6%5.3%

Results and growth

ABBVHAE
Results and growth
Revenue, 12 months$66.0B$1.4B
Net income, 12 months$10.3B$104M
Free cash flow, 12 months$18.9B$298M
Earnings per share, 12 months$5.81$2.26
Revenue growth, year on year8.6%-2.0%
Revenue growth a year, past+5.9%over 5 years+8.9%over 5 years
EPS growth a year, past-2.8%over 5 years+5.8%over 5 years

Margins and returns on capital

ABBVHAE
Margins and returns on capital
Gross margin73.7%59.6%
Operating margin32.2%12.8%
Net margin15.7%7.5%
ROIC25.7%6.3%
ROE–12.1%

Balance sheet

ABBVHAE
Balance sheet
Cash$10.8B$261M
Total debt$80.9B$1.1B
Net debt / EBITDA3.23.0
Interest cover7.1×9.2×

Dividends and buybacks

ABBVHAE
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%3.1%
Shareholder yield2.5%3.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or HAE

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Haemonetics?

By market value, AbbVie ($522B) is about 93.4 times Haemonetics ($5.6B), at today's prices.

How did ABBV and HAE stock do over the last 10 years?

Since November 15, 2016, ABBV's price moved +369.3% and HAE's +216.3%. With dividends: ABBV +605.5% (+21.6% a year), HAE +216.3% (+12.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or HAE?

The dividend yield at today's price is 2.35% for AbbVie and none for Haemonetics. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and HAE?

At today's price, the P/E is 50.7 for ABBV and 53.8 for HAE. The median of the last five years was 57.0 and 36.9, which shows where each stands against its own past.

Which has the higher profit margins, AbbVie or Haemonetics?

Over the last twelve months, the net margin was 15.7% for AbbVie and 7.5% for Haemonetics, and the operating margin 32.2% and 12.8%. Revenue was $66.0B and $1.4B.

Which is the better investment, AbbVie or Haemonetics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.